| Name | Title | Contact Details |
|---|
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.
The NeoStrata Company, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Princeton, NJ. To find more information about The NeoStrata Company, Inc., please visit www.neostrata.com
Wound Care Innovations is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CareOregon Advantage is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Comphealth Associates is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.